Bayer receives approval for Kovaltry® in China for the treatment of children and adults with Hemophilia A

Young scientists experimenting on health and food science topics at Bayer Science Teens Camp in the U.S.

International exchange: Pupils from Germany, India, Africa and the U.S. taking part in two-week, hands-on seminar focusing on life science, medical health and food science topics / Bayer partnering with renowned Center for STEM Learning at University of Colorado in Boulder ...

Bayer continues commitment to improving feline medicine and health with symposium at ISFM congress

Bayer recently supported the International Society of Feline Medicine (ISFM) 2018 European Congress, with platinum sponsorship of the event / A symposium organised by Bayer at the Congress, saw leading experts discuss the latest information on two feline infectious diseases / Key messages included how to minimise the risk of a mycoplasmal infection and the threat of feline leishmaniosis ...

XANTUS programme confirms low bleeding and low stroke rate with Xarelto® in 11,121 prospectively investigated patients with atrial fibrillation

Outcomes from real-world patients with atrial fibrillation (AF) confirm low bleeding and low stroke rates for Xarelto ...

Bayer Animal Health and Mitsui Chemicals Agro sign global license agreement

Bayer to expand its strong parasiticide portfolio for companion animals with new compounds derived from MCAG’s chemical library ...

Seresto® now offers protection with new licensing in many European countries to reduce the risk of canine leishmaniosis

Seresto is now licensed to reduce the risk of infection with Leishmania infantum in dogs via transmission by sandflies for up to eight months in many European countries / Canine leishmaniosis is a vector-borne disease with global significance / L. infantum is zoonotic, potentially causing severe disease in dogs, as well as humans ...

Bayer expands strategic alliance with Broad Institute of MIT and Harvard

Joint Precision Cardiology Laboratory will focus on using innovative technologies to better understand cardiovascular diseases on a molecular level and to pursue new drug targets / Additional investment of up to $22 million over 5 years ...

Bayer supports a new UN code opposing discrimination against lesbian, gay, bisexual, transgender and intersex (LGBTI) people

News Conference Call

Bayer plans closing of Monsanto acquisition on June 7 ...

Bayer concludes refinancing of the Monsanto acquisition by placing bonds with a volume of 5 billion euros

Issue of four tranches with maturities of 4 to 11½ years was more than four times oversubscribed ...